---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000094"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:40:07.000054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design

## Summary
- Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.
- Warrants exercisable at $2.04/share, immediately exercisable, expire July 24, 2028.
- Net proceeds to fund seralutinib development/commercialization and working capital.
- Participation from NEA, EcoR1, Armistice, Farallon, Madison Avenue Partners, and others.
- Interim TORREY OLE data and PROSERA Phase 3 design disclosed via separate 8-K; conference call July 25.

## SEC filing metadata
- accession: 0001728117-23-000094
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/0001728117-23-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/goss-20230719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000094
- JSON: https://secwatch.observer/filing/0001728117-23-000094.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000094.txt

## Key facts
- Material Agreements
  Gossamer Bio, Inc. entered into Purchase Agreement with purchasers named therein, including certain directors and executive officers of the Company valued at approximately $212.1 million (effective 2023-07-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers named therein, including certain directors and executive officers of the Company
  - Value: approximately $212.1 million
  - Effective: 2023-07-19
  source text: On July 19, 2023, Gossamer Bio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein, including certain directors and executive officers of the Company (the “Purchasers”), for the private placement (the “Private Placement”) of 129,869,440 shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/0001728117-23-000094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.